Grifols, a global healthcare company and leading producer of plasma-derived medicines, today announced it has received a grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to ...

The unique plasma assets serve as the foundation of the Chronos-PD program, driving advanced research at Grifols subsidiary Alkahest, which is leading the initiative given its specialization in the ...

As a recognized leader in transfusion medicine, Grifols offers a comprehensive portfolio of solutions designed to enhance safety from donation to transfusion, in addition to clinical diagnostic ...

According to Grand View Research, the European and Middle Eastern drug screening markets are projected to grow significantly by 2030, with Europe expected to reach $3.6 billion 1 and the Middle East ...

Private equity company Brookfield has reportedly moved closer to taking control of Grifols, after months ... other products like blood transfusion diagnostics, which is tax-domiciled in Ireland ...

Quantum Traffic Management transitions from saliva and urine testing to non-invasive, in-house fingerprint sweat-based drug screeningMost recent ...

The Catalan blood products company has received a $21 million grant from the Michael J. Fox Foundation (MJFF) for Parkinson's ...

The global hepatitis diagnostic test market is poised for significant growth, with market value projected to increase from USD 3621.5 million in 2024 to USD 6118.4 million by 2033, reflecting a steady ...

What I think is most exciting is how AI and automation promise to position us to better care for our staff and patients.

including consulting and implementing technology solutions. The Company will operate under the name "Intelligent Protection Management Corp." The Company's common stock will commence trading under ...